Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Novo Nordisk reaches exclusive agreement to market Vagifem 10 mcg

Novo Nordisk Inc. today announced that it has signed an exclusive agreement with Upsher-Smith Laboratories, Inc. to market Vagifem (estradiol vaginal tablets) 10 mcg. Under the terms of the agreement, Upsher-Smith will exclusively market Vagifem 10 mcg to physicians in the U.S. beginning August 2 through the company's existing field sales force.

23 Aug 2010

GM-CSF protein reduces AD pathology, reverses memory loss: Study

A signaling protein released during rheumatoid arthritis dramatically reduced Alzheimer's disease pathology and reversed the memory impairment of mice bred to develop symptoms of the neurodegenerative disease, a new study by the University of South Florida reports. Researchers found that the protein, GM-CSF, likely stimulates the body's natural scavenger cells to attack and remove Alzheimer's amyloid deposits in the brain.

23 Aug 2010

UNT Board of Regents approves new M.D. degree program at UNTHSC

The University of North Texas System Board of Regents today voted to approve a proposal to develop a new M.D. degree program at the UNT Health Science Center at Fort Worth (UNTHSC). The M.D. program will be an independent fifth school in addition to the Texas College of Osteopathic Medicine, Graduate School of Biomedical Sciences, School of Public Health, and School of Health Professions.

21 Aug 2010

U-M launches new program to prevent sports-related injuries

Christopher Roth doesn't remember the train wreck on the practice field: As a University of Michigan fullback, he and another player were running at each other from about 10 yards apart. The resulting collision left him stumbling around, unaware of what he was doing.Like 3 million athletes every year, Roth had suffered a concussion. It wasn't the first time, but this injury ended his football career.

21 Aug 2010

New squeeze test for screening potential drugs for Alzheimer's

Brain cells exposed to a form of the amyloid beta protein, the molecule linked to Alzheimer's disease, become stiffer and bend less under pressure, researchers at UC Davis have found. The results reveal one mechanism by which the amyloid protein damages the brain, a finding that could lead to new ways to screen drugs for Alzheimer's and similar diseases.

21 Aug 2010

Muscular Dystrophy Association awards $14.1M in new grants

The Muscular Dystrophy Association, which has invested almost $39 million in 2010 in worldwide research seeking treatments and cures for muscle diseases, today announced that it has awarded $14.1 million in new grants.

20 Aug 2010

Fenwal's new software release for Autopheresis-C system receives FDA 510(k) clearance

Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance to market a new software release for its Autopheresis-C® system. Blood and plasma centers worldwide use the Autopheresis-C system to collect plasma from donors.

20 Aug 2010

New avenues for stem cell research

According to researchers at the University of NSW a new way has been found to generate stem cells from human skin - known as induced pluripotent stem (iPS) cells. A paper outlining the breakthrough was published this week in the US-based international online journal PLoS One.

19 Aug 2010

Study finds burnout progressively develops among medical students

More than 40 percent of third-year medical students have symptoms of moderate to severe burnout, according to a study in the August Southern Medical Journal, official journal of the Southern Medical Association.

19 Aug 2010

USPTO to issue reexamination certificate for Neuralstem's patent for neural stem cell technology

Neuralstem, Inc. announced that it received notification that the United States Patent and Trademark Office (USPTO) has upheld the patentability, without amendment, of all claims in U.S. Patent No. 5,753,506 and intends to issue a reexamination certificate in due course. This patent describes methods of culturing and expanding neural stem cells.

19 Aug 2010

Cognition Therapeutics receives grant to develop small-molecule drug candidate for Alzheimer's disease

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $228,668 to Cognition Therapeutics (CogRx) to develop small molecule drugs that block the action of the toxic "oligomers" thought responsible for Alzheimer's disease (AD).

19 Aug 2010

New clues to molecular action of Alzheimer's drug memantine

Alzheimer's disease destroys brain cells and their connections (called synapses), causing memory loss and other cognitive problems that disrupt work, hobbies and daily life. Symptoms can be alleviated, in part, by the drug memantine (marketed in the United States as Namenda), which is currently FDA-approved to treat moderate-to-severe Alzheimer's disease and was, in part, developed by Stuart A. Lipton, M.D., Ph.D., Director of the Del E. Web Center for Neuroscience, Aging and Stem Cell Research at Sanford-Burnham Medical Research Institute (Sanford-Burnham).

19 Aug 2010

Overweight, smoking and lack of exercise linked to frequent headaches in teens

Teens who are overweight, get little exercise or who smoke may be more likely to have frequent headaches and migraines than teens with none of these factors, according to a study published in the August 18, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

19 Aug 2010

New 'Pesticide-Induced Diseases Database' tracks published epidemiologic and real world exposure studies

Links to pesticide exposure are being found in a growing number of studies that evaluate the causes of preventable diseases -- including asthma, autism and learning disabilities, birth defects and reproductive dysfunction, diabetes, Parkinson's and Alzheimer's diseases, and several types of cancer. A new database, released today, tracks published epidemiologic and real world exposure studies.

19 Aug 2010

Intellect Neurosciences locks database of OXIGON Phase 1b clinical trial for Alzheimer's disease

Intellect Neurosciences, Inc. a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has locked the database of the Company's Phase 1b clinical trial for its lead Alzheimer's candidate, OXIGON™ (OX1).

18 Aug 2010

Researchers participate in Alzheimer's Breakthrough Ride to urge Congress make the disease a national priority

This summer, more than 55 researchers participating in the Alzheimer's Breakthrough Ride are cycling relay-style across the country, collecting petition signatures asking Congress to make Alzheimer's disease a national priority. The public response to the petition has been so overwhelming that as the Alzheimer's Breakthrough Riders hit the halfway point in their 67-day route from San Francisco to Washington, D.C. on August 18, they are already more than 80% of the way to their goal of 50,000 signatures.

18 Aug 2010

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

18 Aug 2010

Brain trauma in sports associated with motor neuron disease, researchers find

The Center for the Study of Traumatic Encephalopathy at Boston University School of Medicine and Department of Veterans Affairs announced today that they have provided the first pathological evidence that repetitive head trauma experienced in collision sports is associated with motor neuron disease, a neurological condition that affects voluntary muscle movements.

18 Aug 2010

Specific brain abnormalities linked to motor neuron disease in athletes with head trauma

Professional athletes with repetitive head trauma and possibly others with a history of head injuries many years previously may be prone the development of a motor neuron disease similar to amyotrophic lateral sclerosis (ALS or "Lou Gehrig's disease"), reports a study in the September Journal of Neuropathology & Experimental Neurology, official journal of the American Association of Neuropathologists, Inc.

18 Aug 2010

Lilly to halt development of potential Alzheimer's disease drug semagacestat

Eli Lilly and Company will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary results from two ongoing long-term Phase III studies showed it did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living.

18 Aug 2010

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Novo Nordisk reaches exclusive agreement to market Vagifem 10 mcg

GM-CSF protein reduces AD pathology, reverses memory loss: Study

UNT Board of Regents approves new M.D. degree program at UNTHSC

U-M launches new program to prevent sports-related injuries

New squeeze test for screening potential drugs for Alzheimer's

Muscular Dystrophy Association awards $14.1M in new grants

Fenwal's new software release for Autopheresis-C system receives FDA 510(k) clearance

New avenues for stem cell research

Study finds burnout progressively develops among medical students

USPTO to issue reexamination certificate for Neuralstem's patent for neural stem cell technology

Cognition Therapeutics receives grant to develop small-molecule drug candidate for Alzheimer's disease

New clues to molecular action of Alzheimer's drug memantine

Overweight, smoking and lack of exercise linked to frequent headaches in teens

New 'Pesticide-Induced Diseases Database' tracks published epidemiologic and real world exposure studies

Intellect Neurosciences locks database of OXIGON Phase 1b clinical trial for Alzheimer's disease

Researchers participate in Alzheimer's Breakthrough Ride to urge Congress make the disease a national priority

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

Brain trauma in sports associated with motor neuron disease, researchers find

Specific brain abnormalities linked to motor neuron disease in athletes with head trauma

Lilly to halt development of potential Alzheimer's disease drug semagacestat

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in